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Abstract: The Wnt signaling pathway is evolutionarily conserved, regulating both embryonic 
development and maintaining adult tissue homeostasis. Wnt signaling controls several 
fundamental cell functions, including proliferation, differentiation, migration, and stemness. It 
therefore plays an important role in the epithelial homeostasis and regeneration of the 
gastrointestinal tract. Often, both hypo- or hyper-activation of the pathway due to genetic, 
epigenetic, or receptor/ligand alterations are seen in many solid cancers, such as breast, colorectal, 
gastric, and prostate. Gastric cancer (GC) is the fourth commonest cause of cancer worldwide and 
is the second leading cause of cancer-related death annually. Although the number of new 
diagnoses has declined over recent decades, prognosis remains poor, with only 15% surviving to 
five years. Geographical differences in clinicopathological features are also apparent, with 
epidemiological and genetic studies revealing GC to be a highly heterogeneous disease with 
phenotypic diversity as a result of etiological factors. The molecular heterogeneity associated with 
GC dictates that a single ‘one size fits all’ approach to management is unlikely to be successful. Wnt 
pathway dysregulation has been observed in approximately 50% of GC tumors and may offer a 
novel therapeutic target for patients who would otherwise have a poor outcome. This mini review 
will highlight some recent discoveries involving Wnt signaling in GC. 
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1. Gastric Cancer  
Gastric cancer (GC) is the sixth commonest cause of cancer worldwide and the second leading 
cause of cancer-related death [1], and five-year survival rates remain at approximately 18% [2]. 
Treatment options are tailored to each individual patient’s needs but are largely stratified as palliative 
or curative. Following diagnosis, patients undergo a series of investigations to determine a clinical 
stage based on the tumor node metastasis (TNM) staging system [3]. These investigations consist of 
computer tomography (CT) scanning of the thorax, abdomen, and pelvis; staging laparoscopy; and 
in selected cases, positron emission tomography (PET) CT scanning. Patients with evidence of distant 
metastasis or those who are based on concurrent illnesses are commonly offered palliative treatment 
[4].  
GC can be histologically characterized using the Lauren classification, with tumors described as 
either gland-forming adenocarcinoma (intestinal type) or poorly differentiated with infiltrative single 
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cell morphology (diffuse type) [5]. These two subtypes are distinct entities that differ in their 
pathogenesis, etiology, and epidemiology; however, a small number of gastric adenocarcinomas can 
present with features of both subtypes [6]. The intestinal subtype is more commonly diagnosed in 
high-risk populations, such as older males, and tumorigenesis is often associated with H. pylori 
infection [6]. A variation of the diffuse type is the signet ring cell adenocarcinoma and is associated 
with a poor prognosis [7]. Depending on both the degree of local tumor invasion and location of the 
primary tumor, surgical resection with total or subtotal gastrectomy and radical lymphadenectomy 
remains the only treatment modality [8]. The Southwest Oncology Group (SWOG 9008) trial revealed 
that adjuvant chemoradiation in patients undergoing potentially curative surgery for GC or 
junctional esophageal cancer (OC) was associated with improved overall survival (OS); however, the 
post-operative chemoradiation was poorly tolerated [9]. Furthermore, the Medical Research Council 
Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial showed that perioperative chemotherapy 
(Epirubicin, Cisplatin, and 5- Fluorouracil) in patients with GC or junctional OC had a significantly 
higher OS and progression-free survival (PFS) when compared to patients who had surgery alone 
[10]. Unfortunately, there are a number of patients who develop chemotherapy-related morbidity, 
and therefore, simply offering chemotherapy to all patients is not a viable treatment option.  
The prognosis for patients with metastatic GC is very poor, with a median survival varying from 
4 to 9 months depending on the degree of metastatic disease and whether patients receive palliative 
chemotherapy [11]. Although there is a greater understanding of the etiology and pathophysiology 
of GC, identifying novel and reliable therapeutic targets is a challenge facing academics and clinicians 
alike. There is growing evidence highlighting the central role of the Wnt signaling pathway in GC 
development and progression. This review will explore the Wnt signaling pathway in both the 
initiation and progression of GC, and how the pathway can be therapeutically targeted.  
2. Wnt Signaling 
There are 19 highly conserved Wnt ligands, described as secreted morphogens that carry out 
their function from medium to long distance ranges that elicit several signaling pathways. Whether 
Wnt ligands act locally or distantly is dependent on how the Wnt ligands are released. Wnt ligands 
can be released from the plasma membrane directly, as part of an exosome or lipid protein particles, 
or can be tethered to the plasma membrane [12]. The varying mechanisms of how Wnt ligands are 
released explains their diverse role during the development and maintenance of organs. Wnt ligands 
can bind, with varying affinities, to a heterodimeric receptor complex of Frizzled receptors (Fzd1-10) 
and their co-receptors, low-density lipoprotein receptor-related protein 5/6 (LRP5/6), receptor 
tyrosine kinase-like orphan receptor 2 (ROR2), and related to receptor tyrosine kinase (Ryk), to 
initiate either β-catenin-dependent (canonical) or β-catenin-independent signaling (non-canonical) 
[13]. Wnt proteins are palmitoylated by the o-acyl transferase porcupine [14], which, together with 
Wntless/Evi, is required for the secretion of Wnt ligands [12,15]. Members of the R-spondin (Rspo) 
family are also extracellular positive regulators of Wnt signaling. Rspo binds to leucine-rich repeat 
containing G protein-coupled receptors 4-6 (LGR4-6), preventing the activity of the two homologues 
E3 ubiquitin ligases RNF43 and ZNRF3, leading to an accumulation of Fzd receptors on the cell 
surface. However, in the absence of Rspo binding, Fzd receptors are targeted for lysosomal 
degradation by RNF43/ZNRF3 [12].  
In the absence of Wnt signaling, cytoplasmic β-catenin is targeted by ubiquitin-directed 
degradation by the intracellular regulator: The β-catenin destruction complex [15]. This destruction 
complex is composed of the intracellular scaffold proteins AXIN, adenomatous polyposis coli (APC), 
casein kinase 1α (CK1α), and glycogen synthase 3 (GSK3α/β), which targets β-catenin by catalyzing 
the phosphorylation of a phospho-degron at the N-terminus. Activation of the canonical Wnt 
pathway, through the binding of canonical Wnt ligands (such as Wnt3a), causes dimerization of the 
Fzd receptor and LRP5/6 co-receptor, and leads to phosphorylation of the cytoplasmic tail of LRP5/6, 
recruiting disheveled (DVL) and AXIN to the cell membrane [15]. The destruction complex is now 
no longer able to degrade β-catenin, leading to an increase of cytoplasmic β-catenin. β-catenin then 
translocates to the nucleus, where it acts as a transcription co-activator, by binding to members of the 
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T-cell factor/lymphoid enhancer factor (TCF/LEF) family, and CREB-binding protein (CBP) to 
modulate transcription of Wnt target genes. In the absence of canonical Wnt signaling, TCF/LEF 
family activity is repressed by interaction of the Groucho/ transducin-like enhancer of split (TLE) 
family of co-repressors [15]. The canonical Wnt signaling pathway is essential for determining the 
cell fate and the proliferation and self-renewal of both stem and progenitor cells [16]. Recently, two 
transcriptional regulators of the Hippo pathway, YAP/TAZ, have been identified as novel regulators 
of Wnt signaling [12]. In the absence of Wnt ligands, YAP/TAZ form part of the destruction complex, 
recruiting β-TrCP, and dampening Wnt signaling. YAP/TAZ have a dual role in Wnt signaling, as 
activation of the signaling cascade causes displacement of YAP/TAZ and β-TrCP from AXIN1 by LRP 
during degradation of the destruction complex. The contradicting role of YAP/TAZ in Wnt signaling 
highlights that there is substantial crosstalk between the Wnt and Hippo pathway [12].  
The non-canonical Wnt signaling pathway occurs via a transcriptional β-catenin-independent 
signal transduction and can be broadly categorized into the planar cell polarity (PCP) and the 
Wnt/calcium (Wnt/Ca2+) pathway [17]. Binding of Wnt5a, Wnt7a, Wnt8a, or Wnt11 (non-canonical 
Wnts) to Fzd receptors and their respective co-receptors ROR2 and RYK initiates the PCP pathway. 
The PCP pathway was first described in Drosophila and is determined by the asymmetrical location 
of core PCP components (proximal and distal subsets). The proximal subset includes the atypical 
cadherin flamingo (FMI), the LIM domain protein prickle (PK), and the Van Gogh transmembrane 
protein (VANG1/2). The distal subset includes Fmi, Fzd receptors, DVL, and ankyrin repeat protein 
Diego (DGO), and it is the intercellular interactions between these subsets that allow for the 
asymmetrical localization of these core PCP proteins [16].  
Rac1 and RhoA (Rho GTPases) are effectors of cytoskeletal rearrangement. Activation of PCP 
signaling causes both RhoA and Daam1 to interact with DVL, leading to ROCK1 activation, 
mediating cytoskeletal rearrangement [16]. The disparity in Wnt ligand/receptor complexes allows 
for variation in the transmission of signaling, resulting in the activation of genes, such as c-jun, Cdc42, 
and DVL. PCP can also be activated upon binding of syndecan4 (SDC4) and R-SPO to Fzd7, 
transmitting Wnt5a (non-canonical Wnt)-induced internalization of the ligand/receptor complex [17].  
In vertebrates, Wnt ligands can activate Ca2+-dependent events through the release of 
intracellular Ca2+. The Wnt/Ca2+ was first identified in zebrafish, where overexpression of Wnt5a 
induced an increase in Ca2+ signaling, and in Xenopus caused the activation of protein kinase C (PKC) 
[18,19]. Initiation of Wnt/Ca2+ signaling through Fzd/ROR1/2 interaction activates inositol 1,4,5-
triphosphate (IP3), 1,2-diacylglycerol (DAG) and Ca2+ by phospholipase C (PLC). PLC is responsible 
for the modification of IP3 and DAG, allowing IP3 to interact with Ca2+ channels on the endoplasmic 
reticulum, thus causing the release of Ca2+ ions. DAG can then work with Ca2+ ions to activate PKC. 
Further, Ca2+ activates calmodulin-dependent protein kinase II (CaMKII), which works with PKC to 
activate both CREB and NFκB to regulate gene transcription [19].  
Recently, a novel arm of non-canonical Wnt signaling known as the Wnt/STOP pathway (Wnt-
dependent stabilization of proteins) was discovered. Canonical Wnt signaling peaks during the G2/M 
phase of the cell cycle as LRP6 is primed by Cyclin Y/CDK14, and at this point, activation of β-catenin-
independent stabilization of proteins is seen, leading to inhibition of GSK-3β activity. This prevents 
degradation of multiple proteins, resulting in an increased cell protein content, essential for cellular 
division [16]. 
We do not fully understand how Wnt ligands travel between cells to exert their long-range 
signaling activity, with both secreted- and membrane-associated mechanisms observed. Extracellular 
factors, such as Swim [20], Frzb, and Cres [21], can promote the solubility and diffusion of Wnt proteins 
and enhance their activity. However, membrane-associated mechanisms have also been identified, 
including the transport of Wnt in exosomes [22] and cytonemes (dynamic actin-based membrane 
structures known as signaling filopodia) [23]. Interestingly, cytoneme formation is regulated by Wnt 
signaling to activate paracrine Wnt/PCP signaling, whilst in neighboring cells, cytoneme-associated 
Wnt8a activates β-catenin-dependent Wnt signaling [24]. 
3. Deregulated Wnt Components in GC 
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Genomic analysis identified 46% (range 43%–48%) of gastric tumors exhibit deregulation of the 
Wnt/β-catenin pathway [25]. Several Wnt ligands are upregulated in human gastric tumors, 
including WNT1 [26], WNT2b [27], WNT5a [28], WNT6 [29], and WNT10a [30] (Table 1). These Wnt 
ligands are also upregulated in the gastric tumors of gp130F/F mice [31].  
Moreover, in 13/15 GC cell lines, nuclear localization of endogenous β-catenin is observed, with 
a subsequent increase in TCF/LEF transcriptional activity, confirming aberrant canonical Wnt 
signaling in GC cells [32]. Loss of function of APC is often due to hypermethylation of the promoter 
region or gene mutation. Wang et al. [33] found 9 out of 16 high-grade gastric adenomas had 
methylation of the APC promoter, which correlated with the grade of dysplasia and abnormal 
expression of β-catenin. Deregulation of Wnt signaling by truncation of Apc is able to trigger 
tumorigenesis in the antrum [31] or the corpus [34] in mice, although compound mutant Kras:Apc 
mice are more commonly used in experiments to investigate the cell of origin in the corpus [35]. 
Further, the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway database identifies the 
Wnt pathway as the third most active in gastric tumors, with RNF43, AXIN1/2, CTNNB1, and APC 
frequently mutated [5]. Additionally, almost 30% of microsatellite instability (MSI) high GCs have a 
frameshift mutation in AXIN2 [36] and genetic deletion of Gsk3β, leading to aberrant Wnt signaling, 
which drives rapid gastric tumor formation in mice [37].  
The non-canonical Wnt pathway has also been implicated in GC. High protein expression of the 
non-canonical Wnt5a ligand was observed in 71 out of 237 primary GC patient samples (both 
intestinal and diffuse type), and these samples were positively associated with the depth of invasion 
and the degree of lymph node metastasis [38]. Further, an in vivo xenograft model showed that the 
injection of metastatic GC cells with stable Wnt5a knockdown into the spleen of nude mice 
significantly decreased the number of liver metastatic nodules when compared to control GC cell 
lines [39]. Wnt5a also regulates GC migration and invasion in vitro and treatment with an anti-Wnt5a 
antibody significantly reduced the number of metastatic liver foci compared to a control antibody in 
xenografts [40]. However, this was only seen in one GC cell line, KKLS, whilst MKN45 GC cells were 
still able to metastasize during Wnt5a antibody treatment. Although this evidence does suggests a 
role for Wnt5a in GC development, further research is needed to elucidate the exact role it has in vivo 
and where the source of the ligand is coming from (tumor vs. microenvironment) [41].  
Recently, deregulation of Wnt components at the level of the ligand/receptor has been identified, 
which in several cancers, including gastric, lung, glioblastoma, breast, melanoma, and prostate, are 
often more frequent than the deregulation of cytoplasmic components [42].  
Epigenetic silencing of Wnt antagonists that regulate the pathway at the level of the 
ligand/receptor have been identified in gastric tumors. Dickkopf 1/2 (DKK1/2) are both antagonists 
of canonical Wnt signaling that bind to LRP5/6, preventing their interaction with Wnt-Fzd complexes. 
Wang et al. [43] showed that both DKK1/2 were hyper-methylated in GC patient samples when 
compared to adjacent normal tissue. Further, hierarchical clustering of GC samples revealed DKK2 
and secreted Frizzled-related protein 2 (sFRP2) to be concurrently hypermethylated [43]. sFRPs are a 
family of five secreted glycoproteins with an extracellular cysteine-rich domain, which downregulate 
Wnt signaling by binding to Fzd receptors. To corroborate the hyper-methylation of DKK2 and sFRP2, 
mRNA expression of both genes was analyzed, and showed that gene transcripts were lower in GC 
samples when compared to normal adjacent tissue, suggesting the hypermethylation was responsible 
for the silencing of these genes [43]. sFRP-1, 2, or 5 were shown to inhibit Wnt signaling in GC cell 
lines, which reduced proliferation and increased apoptosis [32] whilst overexpression of sFRP-2 was 
able to inhibit the proliferation of gastric xenografts [44]. Conversely, sFRP4 is also part of a four-
gene single-patient classifier (SPC) signature, reported to help predict which GC patients are at high 
risk [45], and thus sFRPs have a diverse role in regulating GC biology.   
Adenovirus (chimeric Ad5/35 vector)-mediated DKK1 overexpression was seen to decrease 
viability, anchorage-independent colony formation, and invasion of CD44+ GC cells through 
inhibition of canonical Wnt signaling [46]. Further, DKK1 overexpression significantly impeded the 
tumorigenesis of CD44+ GC cells in vivo [46]. These data suggested that chimeric Ad5/35 vector-
mediated DKK1 overexpression could be a suitable gene therapy for targeting CD44+ cancer stem 
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cells in GC. Further, Hong et al. reported that DKK1 expression was higher in tumors with lymph 
node metastasis, and patients with high DKK1 expression had a shorter OS and disease-free survival 
[47].  
High expression of the RYK co-receptor (initiates non-canonical Wnt signaling) was found to be 
correlated with poor differentiation, high TNM stage, and liver metastasis in GC patients (cohort of 
250 patients) [48]. Subcutaneous injection of GC cells with stable RYK knockdown into mice showed 
reduced tumor growth, and increased survival compared to RYK-proficient control mice. Tail vein 
injection of the RYK knockdown GC cells significantly reduced the number of mice bearing liver 
tumor nodules (4/12 mice) when compared to control mice (10/12), suggesting RYK plays a role in 
both GC initiation and metastasis [48].  
Whole genome sequencing of 100 tumor-normal pairs identified that 54.6% of MSI tumors had 
mutations in the E3 ubiquitin ligase RNF43 gene, of which 62.5% were a truncating mutation [5]. 
Furthermore, a study carried out by Nui et al. [49] demonstrated that mRNA and protein expression 
of RNF43 was significantly lower in GC cell lines when compared to normal gastric epithelial cells. 
This result was corroborated by the same phenotype seen in primary gastric carcinoma tissue when 
compared to matched normal mucosal tissue [49]. Further, the RNF43 expression that was seen in the 
gastric carcinomas was highest in the well-differentiated tumors and lowest in poorly differentiated 
tumors. A decrease in RNF43 expression was also seen with the progression of the pTNM stage. 
Overexpression of RNF43 in GC cell lines elicited a decrease in proliferation with an increase in 
apoptotic cells, due to upregulation of p53 and cleaved caspase 3 [49].  
Functional analysis demonstrated that deletion of Rnf43 together with closely related Znrf3 
triggered tumorigenesis in the intestine that is dependent on a Wnt-secreting niche. Blocking of this 
Wnt-secreting niche via porcupine inhibition attenuated the hyperplasia without affecting normal 
crypts [50]; however, this has yet to be demonstrated in the stomach. 
These data demonstrate that deregulation of Wnt signaling at the level of the ligand/receptor 
can modulate the initiation, growth, and progression of gastric tumors, highlighting that this part of 
the Wnt pathway is an attractive target for therapeutic intervention in GC.  
To establish whether targeting of the Wnt signaling pathway at the level of the ligand/receptor 
would be therapeutically beneficial for GC, we recently published a paper identifying that 
pharmacologically targeting Fzd receptors or specific genetic deletion of Fzd7 inhibited the initiation 
and growth of gastric tumors in vitro and in vivo [31]. Here, we review the key findings of that paper 
and expand on the therapeutic potential of this strategy to target Wnt signaling at the ligand/receptor 
level. Table 1 summarizes Wnt signaling deregulation in GC.  
4. Fzd7 in Gastric Cancer 
Of the 10 Fzd receptors, Fzd2, 5, 7, 8, and 9 have been shown to be upregulated in GC tissue [51], 
with recent evidence from our group that Fzd7 is important in transmitting Wnt signaling in gastric 
tumors to drive tumor initiation and growth [31]. Overexpression of Fzd7 is seen in late-stage clinical 
GC, correlating with a significantly shorter survival time, where the median survival time of patients 
with high Fzd7 expression drops from 77 months to 23.5 months [52]. Further, knockdown of Fzd7 
reduced proliferation, migration, epithelial-to-mesenchymal transition (EMT), and expression of 
stem cell markers in GC cell lines, through inhibition of canonical Wnt signaling [52].   
Fzd7 is abundantly expressed in GC cell lines, and in the tumors of the Stat3-driven gp130F/F 
mouse model of GC [53]. Pharmacologically targeting Fzd receptors with (OMP-18R5/Vantictumab) 
or inhibiting porcupine with IWP-2 reduced the ability of both APC mutant and APC wild-type (wt) 
GC cells from forming anchorage-independent colonies [31]. This emphasizes that Fzd receptors are 
a therapeutically viable target even in GC tumors with downstream Wnt mutations. Saito-Diaz et al. 
[54] recently showed that LRP5 knockdown inhibits Wnt signaling in APC mutant colorectal cancer 
cell lines (CRC). However, IWP-2 had no effect on Wnt signaling in the same APC mutant CRC cell 
lines, suggesting that further research is needed to determine which Wnt-driven cancers are sensitive 
to porcupine inhibitors and what are the molecular mechanisms behind its function.   
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The molecular targets of OMP-18R5/Vantictumab are Fzd1, 2, 5, 7, and 8. Both Fzd2/7 were 
shown to be highly expressed in GC cell lines, thus indicating that either Fzd2/7 was responsible for 
transmitting Wnt signaling in GC cells [31]. Previous data suggests that Fzd2 is unable to compensate 
for Fzd7 loss in the intestinal epithelium [55]. Genetically targeting Fzd7 in vivo or shRNA-targeted 
knockdown of Fzd7 in vitro showed that Fzd7 was essential for the growth and initiation of GC cells 
[31].  
Deletion of Fzd7 in the normal gastric epithelium is deleterious, resulting in rapid repopulation 
with Fzd7-proficient cells [55]. In the gastric adenomas of Cre+ gp130F/F Fzd7fl/fl mice, Fzd7-deleted cells 
were not repopulated but rather survived 20 days post-tamoxifen induction [31] and are thus unable 
to respond to Wnt signaling, and subsequently failed to proliferate. This mechanism, whereby Fzd7-
deficient cells survive in the tumor but do not proliferate, is different from the repopulation observed 
in the normal gastric epithelium following Fzd7 deletion and reflects the aberrant biology of tumors 
compared to the normal epithelium.  
A pivotal risk factor for developing GC is infection with H. pylori; however, the mechanism of 
how infection causes GC is currently unknown. Interestingly, it has been found that H. pylori can 
activate the Wnt/β-catenin pathway through upregulation of Fzd7, which was associated with H. 
pylori infection-induced cell proliferation. Knockdown of Fzd7 in H. pylori-infected GC cells 
suppressed both cell proliferation and colony formation [56]. To further elucidate how Fzd7 regulates 
H. pylori-infected gastric carcinogenesis, miRNAs involved in GC were explored. Through 
bioinformatic analysis and functional assays, it was found that miR-27b harbored a putative binding 
site for Fzd7 3-UTR [56]. Further, it was found that miR-27b was able to suppress H. pylori infection 
and the Wnt signaling pathway through inhibition of Fzd7 [56]. A study carried out by Song et al. 
[57] showed that H. pylori caused an upregulation of TRPC6 (transient receptor potential cation 
channel) expression, by regulating the Wnt/-βcatenin pathway, thus promoting GC progression. 
Thus, targeting Fzd7 with specific miRNAs could be a therapeutic strategy for GC.  
c-Myc is a well characterized β-catenin/TCF target gene within the gastrointestinal tract. Both 
GC cells and mouse gastric adenomas show upregulation of c-Myc in an Fzd7-dependent manner 
[31]. Conditional deletion of c-Myc in Cre+;Apcfl/fl;Mycfl/fl mice showed a dramatic reduction of gastric 
adenoma initiation and Wnt activation compared to the respective controls, identifying c-Myc as a 
key modulator of gastric tumor growth downstream of Fzd7 [31]. Deletion of c-Myc in the intestinal 
epithelium is deleterious and triggers rapid repopulation [58]. We recently identified that this role is 
not conserved in the gastric epithelium, with the deletion of c-Myc leading to no changes in stem cell 
activity or homeostasis in vivo [59]. Thus, any future therapy in which c-Myc levels are reduced, 
including targeting Wnt signaling, or specifically c-Myc itself for the treatment of GC, would be well 
tolerated in the stomach. 
There are very few functional experiments that decipher the role of other Fzd receptors, besides 
Fzd7 in GC. Interestingly, Fzd6 is downregulated in GC tissue samples and cell lines, and 
overexpression of Fzd6 was able to suppress both the proliferation and migration of GC [60], thus 
Fzd6 would not be a viable therapeutic target for GC.  
5. Targeting Wnt Signaling at the Receptor Level in Cells with Downstream Mutations  
Wnt signaling is frequently deregulated in several cancers by mutations of the cytoplasmic 
components of the pathway, including APC or β-catenin. However, APC mutant cells do not simply 
switch on Wnt signaling, but rather, regulation is permissible at other levels of the pathway. This is 
well illustrated by the observation that APC mutant tumors display a variable intensity of nuclear β-
catenin, suggesting an environmental factor can regulate APC mutant cells [42,61]. This raises the 
question of whether Wnt signaling can be targeted at the level of the ligand/receptor even in cells 
with mutant APC. Recently, Saito-Diaz et al. [54] showed that APCKO CRC cells induced the formation 
of the signalosome (Wnt receptor complex), resulting in activated Wnt signaling. However, CRC cells 
with APC mutations treated with IWP-2 did not inhibit the activation of the signalosome, suggesting 
that Wnt ligands are dispensable in Wnt pathway activation resulting from APC truncation. 
Interestingly, LRP6 deletion in SW480 and DLD1 cells (both APC mutant) did inhibit canonical Wnt 
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signaling and decreased cytoplasmic levels of β-catenin. These data suggest the Wnt receptor 
signalosome is activated by mutant APC and can induce Wnt signaling independent of Wnt ligands. 
Saito-Diaz et al. [54] also showed that rapid activation of Wnt signaling by the signalosome in APC 
mutant cells was due to internalization of the complex via clathrin-dependent endocytosis. Similarly, 
recent work from Owen Sansom’s group showed that GTPases RalA and RalB were required for 
efficient internalization of Fzd7 to activate Wnt signaling in intestinal stem cells [62], illustrating a 
conserved mechanism of internalization of the signalosome in wt and APC mutant cells.  
Schatoff et al. [63] demonstrate that CRC cells with a mutation in the mutation cluster region 
(MCR) of APC can respond to Tankyrase inhibition, suppressing oncogenic signaling in response to 
AXIN1/2 stabilization. However, CRC cells containing an early truncating mutation (APCmin) were 
unresponsive to tankyrase inhibition, suggesting repression of Wnt signaling through tankyrase 
inhibition is highly dependent on specific APC disruption. We recently demonstrated that GC 
organoids derived from Tff1CreERT2/+;Apcfl/fl mice treated with the porcupine inhibitor IWP-2, 
prevented upregulation of the Wnt pathway and was associated with reduced organoid proliferation 
[31]. These data suggest a difference in how APC mutant GC and CRC cells respond to different Wnt 
inhibitors depending on the location of the mutation in the APC gene. 
6. Wnt Signaling in Metastatic GC  
A recently published study from the Surveillance, Epidemiology and End Results database 
(SEER) showed that 7792 out of 19,022 (41%) patients presented with metastatic GC, predominantly 
in the liver (3218 patients) [64]. Another study highlighted that patients undergoing curative 
gastrectomy had an overall recurrence rate of 21%, and the most common site of metastasis was the 
peritoneum, followed by liver metastasis, and patients undergoing a curative gastrectomy had para-
aortic lymph node (PALN) metastases (8%-28% of patients) [64]. A study carried out by Riihimaki et 
al. [65] found that male patients with gastric cardia cancer had more metastases found in the nervous 
system, lung, and bone, whereas patients with non-cardia cancer showed more peritoneal metastases. 
Patients with metastatic GC have a median survival of 3 months; however, patients with bone or liver 
metastasis had a worse survival of 2 months [65]. Thus, an understanding the molecular mechanisms 
driving metastatic disease is essential to develop novel targeted therapies and improve the current 
abysmal survival rate.  
It is well established that Wnt signaling not only drives the initiation of solid cancers but also 
contributes to the metastatic progression of the primary tumor. The reactivation of Wnt signaling in 
the cancer stroma favors cancer stem cell survival. Further, the reactivation of Wnt signaling in the 
primary tumor aids the epithelial-mesenchymal transition (EMT) of tumor cells, the migration and 
invasion of tumor cells, and escaping dormancy at metastatic secondary sites [66]. Thus, targeting 
Wnt signaling is an attractive therapeutic strategy for cancer metastasis.  
Though there are limited studies on Wnt signaling driving metastatic GC, Li et al. [67] 
discovered that ADAM17 (TNF-α-converting enzyme) mediates GC cell migration through 
regulation of both the NOTCH and Wnt signaling pathway, evidenced by gene set enrichment 
analysis. ADAM17 was shown to be highly expressed in primary GC tissue, metastatic lymph node 
tissue, and in metastatic GC cell lines. Further, knockdown of ADAM17 in a metastatic GC cell line 
suppressed canonical Wnt signaling through β-catenin downregulation [67].  
Further, the microRNA miR-544a was found to induce EMT through the activation of Wnt 
signaling in GC. Specifically, overexpression of miR-544a induced the translocation of β-catenin from 
the cytoplasm to the nucleus, increasing canonical Wnt signaling in GC cells (MKN28s) [68]. 
Alongside an upregulation of canonical Wnt signaling, miR-544a upregulation downregulated 
protein expression of the Wnt destruction complex protein AXIN2 [68]. 
More so, the stem cell marker LGR5 was found to promote proliferation, invasion, and migration 
of GC cells through the regulation of canonical Wnt signaling [69] as GC cells treated with the 
porcupine inhibitor (C-59) dampened LGR5-induced proliferation and migration of GC cells, 
whereas Wnt3a-treated cells rescued the LGR5-induced phenotype. This was further evidenced by 
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LGR5 overexpression inducing the translocation of β-catenin to the nucleus, and increasing the gene 
expression of two Wnt gene targets, AXIN2 and TCF1 [69]. 
LGR5 overexpression increased GC cell motility by inducing a morphological change, as cells 
became elongated with a fibroblast-like appearance and this phenotype was reversed when the GC 
cells were treated with C-59, suggesting that LGR5 regulates cell migration through Wnt signaling 
[69]. This is consistent with recent work showing that cytonemes are induced by autocrine Wnt8a 
binding to the Ror2 receptor [24]. Activation of cytonemes through Wnt8a binding to Ror2 mediates 
the transport of Wnt8a to surrounding cells, and these receiving cells then trigger canonical Wnt 
signaling [24], highlighting the cross-talk between non-canonical and canonical Wnt signaling in 
migrating cells.   
A study carried out by Hanaki et al. [40] discovered that Wnt5a-targeted knockdown in GC cell 
lines reduced cell migration both in vitro and in vivo through inhibition of Rac1 and laminin ϒ2, both 
key drivers of GC cell invasion. Further, suppression of Wnt5a using an anti-Wnt5a antibody 
prevented the clathrin-mediated rapid internalization of the Wnt5a-Fzd2 receptor complex [40]. 
Together, these data identify Wnt signaling either at the ligand/receptor level, or internalization of 
the receptor complex as an important mechanism driving GC metastasis, and therefore could be 
considered as attractive therapeutic targets.  
7. Clinical Applications of Wnt Inhibitors for GC 
Surgery remains the primary modality of cure in GC. Unfortunately, in the UK, approximately 
35% of patients present with unresectable or metastatic disease [70]. The surgery offered depends on 
the location of the tumors. For example, patients with GC in the antrum are offered a subtotal 
gastrectomy and patients with GC in the body or cardia are offered a total gastrectomy. Despite 
improvements in the treatment of GC, approximately 25%-30% of patients still develop disease 
recurrence and ultimately die of their disease, and additional ‘targeted’ treatments are needed [71].  
It is possible to pharmacologically target Wnt signaling at several places in the pathway (Figure 
1), which is portrayed in a number of current clinical trials [13] (Table 2). Table 2 summarizes the 
current Wnt pathway inhibitors in clinical trials. There are 23 clinical trials that are recruiting or have 
been completed using the Wnt pathway as a therapeutic target. These trials are exclusively looking 
at advanced or metastatic disease and these results may not translate to patients undergoing 
potentially curative surgery, and this is a particularly important future research direction. A precision 
cancer model using preclinical platforms, such as organoids and tumor genomic sequencing, may 
facilitate the prescription of adjuvant therapies to patients who have undergone potentially curative 
treatment who are at a higher risk of relapse. This type of approach is being used in many cancer 
types where patient-derived organoids are helping to predict patient response to chemotherapy in 
real time and directly inform clinical decisions [72].  
Very few of the available pharmacological agents that target the Wnt pathway have been tested 
in preclinical human GC platforms. This may explain why there are no GC-exclusive Wnt inhibitor 
trials in the pipeline. Nevertheless, there is evidence to support a program of Wnt inhibitor research 
in GC. In MKN28 (APC mutant) cells and Apc mutant gastric organoids [31], IWP-2, a porcupine 
inhibitor, suppressed proliferation, and Vanticumab, a Frizzled inhibitor, reduced the number of 
anchorage-independent colonies [31]. In a phase Ib study of patients with stage IV pancreatic cancer, 
Ipafricept, an FZD8 inhibitor, in combination with nab-paclitaxel and gemcitabine, resulted in a 
34.6% partial response rate and a 46.2% stable disease rate, with 80.8% of patients receiving a clinical 
benefit [73]. Given that nearly 50% of GC patients have dysregulation of Wnt signaling, these data 
are promising and worthy of further study.   
Wnt inhibitors are largely very well tolerated in phase 1 clinical trials. The principle adverse 
event of administering Wnt inhibitors is iatrogenic osteopenia and pathological fractures. Therefore, 
many therapeutic regimens now incorporate a supplementary bisphosphonate inhibitor, such as 
zolendronic acid [74]. This has reduced pathological fracture rates from 4.3% [75] to 0% [73]. Other 
adverse effects include nausea, vomiting, diarrhea, fatigue, and abnormal liver function [75]. 
Therefore, Wnt inhibitor therapy has a positive pharmacological profile with promising anti-tumor 
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activity and easily managed and reversible adverse event profiles. Interestingly, a recent study 
showed that ibuprofen can also reduce the proliferation and stemness of GC cells, via inhibition of 
the Wnt pathway [76]; however, additional in vivo studies will be required to fully understand this 
process. 
 
Figure 1. Wnt pathway drug targets. Wnt ligand release, Wnt ligand–receptor interaction, regulators 
of Wnt antagonists, stabilization of the destruction complex, disheveled (DVL) activation, or 
disruption of β-catenin co-activators in the nucleus can all be therapeutically targeted. Frizzled (Fzd), 
R-spondin (R-SPO), leucine-rich repeat containing G protein-coupled receptor (LGR), secreted 
frizzled-related protein (sFRP), Dickkopf-related protein (DKK), low-density lipoprotein receptor 
(LRP), adenomatous polyposis coli protein (APC), CREB-binding protein (CBP), casein kinase 1 
(CK1), T cell factor (TCF). 
Table 1. Summary of Wnt signaling deregulation in GC. 
Wnt Component Role in GC 
Cytoplasmic  
APC 
Mutated/deep deletion in GC patient datasets [31]. Promoter hypermethylation in high grade 
gastric adenomas [33].  
 β-catenin 
Endogenous nuclear expression seen in 13/15 GC cell lines with a subsequent increase in 
TCF/LEF transcriptional activity [32]. Abnormal nuclear expression seen in high grade gastric 
adenomas [33].  
AXIN2 
miR-544a targeted protein downregulation in GC cells [68]. 30% of MSI high GCs have a 
frameshift mutation [36]. 
 Gsk3β Genetic deletion causes rapid gastric tumor formation in mice [37]. 
Wnt target genes  
MYC 
Gene amplification in GC patient samples [36]. GC cells and mouse adenoma show gene 
upregulation in an Fzd7-dependent manner [31].  
LGR5 Overexpression regulates GC cell proliferation, migration, and invasion [69].  
Wnt ligands  
WNT1 Upregulated in human GC tissue. Overexpression accelerates gastric cancer stem cells [26].  
WNT2b Upregulated in GC tissue [27].  
Wnt3a Upregulated in gp130F/F gastric tumors [31]. 
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WNT5a 
High protein expression in GC patient samples, positively associated with the depth of tumor 
invasion and degree of lymph node metastasis [28]. 
WNT6 
Upregulated in GC patient samples and GC cell lines. Expression positively correlated with 
tumor stage and node status [29]. 
WNT10a Upregulated in GC cells and primary GC tissue [30].  
Wnt antagonists  
DKK1 Hypermethylated in GC patient samples [46]. 
DKK2 Hypermethylated in GC patient samples + gene transcripts lower in GC patient samples [43]. 
sFRP2 
 
Concurrently hypermethylated with DKK2 + gene transcripts lower in GC patient samples 
[43].   
Wnt receptors  
RYK co-receptor  
High expression correlated with poor differentiation, high TNM stage and liver metastasis in 
GC patients [48].  
RNF43 
Truncating mutation in MSI GC tumors [5]. Protein expression is significantly lower in GC 
cells than normal gastric epithelial cells [49].  
FZD2  
Upregulated in GC cells (TMK1, MKN7, MKN28, MKN45, MKN74, and KATO-III) and in 
4/10 primary GC tissue [51]. 
FZD5  Upregulated in GC cells (MKN45) [51].  
FZD7 
Overexpression is seen in late-stage clinical GC, correlating with a decrease in survival time 
[52]. Knockdown significantly reduces GC cell proliferation, migration, EMT, and expression 
of stem cell markers [52].  
FZD8 Upregulated in 4/10 primary GC tissue [51]. 
FZD9 Upregulated in 2/10 primary GC tissue [51]. 
 
Table 2. Wnt pathway inhibitors in current clinical trials. 
WNT 
PATHWAY 
TARGET 
DRUG 
PHASE AND 
CLINICAL TRIAL 
 CANCER TYPE 
PORCUPINE 
LGK974 
(WNT974) 
Phase I 
NCT01351103 
Phase I/II 
NCT02278133 
[77] 
Pancreatic Cancer, BRAF mutant CRC, Melanoma, Triple negative Breast 
Cancer, Head and Neck Squamous Cell Cancer, Cervical Squamous Cell 
Cancer, Esophageal Squamous Cell Cancer, Lung Squamous Cell Cancer 
Metastatic Colorectal cancer 
ETC-1922159 
Phase IA/B 
NCT02521844 
[78,79] Advanced or metastatic solid tumors  
RSPO3 OMP131R10 
Phase I 
NCT02482441 
[80] 
Metastatic Colorectal Cancer, advanced relapsed or refractory solid 
tumors 
WNT5A 
RECEPTOR 
Foxy-5 
Phase I 
NCT02020291    
[81] 
Metastatic Breast, Colon or Prostate cancer (loss or reduced Wnt5a on 
IHC) 
 
Phase I 
NCT02655952 
[82] 
Metastatic Breast, Colon or Prostate cancer (loss or reduced Wnt5a on 
IHC) 
WNT FAMILY 
OMP-54F28 
(Ipafricept) 
Phase I 
NCT01608867 
[83] 
Metastatic or unresectable solid tumors 
 
Phase I 
NCT02092363 
[84] 
Ovarian, primary peritoneal or fallopian tube cancer 
 
Phase I 
NCT02069145 
[85,86] 
Locally advanced or metastatic Hepatocellular Carcinoma 
 
Phase I 
NCT02050178 
[87,88] TNM stage IV Ductal adenocarcinoma of the pancreas 
FZD1,2,5,7,8 
OMP-18R5  
(Vantictumab) 
Phase I 
NCT01345201 
[89] 
Metastatic solid tumors with no other standard treatment options 
 
Phase I 
NCT01957007 
[90] 
Recurrent of TNM stage IV Non-small cell lung cancer 
 
Phase I 
NCT01973309 
[91] 
Recurrent or metastatic breast cancer (HER2 overexpression not eligible) 
 
Phase I 
NCT02005315 
[92] TNM stage IV Ductal adenocarcinoma of the pancreas 
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FZD10 OTSA101 
Phase I 
NCT01469975 
[93,94] Progressive synovial sarcoma 
ROR1 
UC-961  
(Cirmtuzumab) 
Phase I 
NCT02222688 
[95] 
Relapsed or refractory B cell Chronic Lymphocytic Leukemia (CLL) 
 
Phase I 
NCT02860676 
[96] 
Relapsed or refractory B cell CLL 
 
Phase I/II 
NCT03088878 
[97] 
B Cell CLL, Small Cell Lymphocytic Lymphoma, Mantle Cell Lymphoma 
 
Phase I 
NCT02776917 
[98] Metastatic or locally advanced HER2 negative breast cancer 
CREB BINDING 
PROTEIN 
PRI-724 
Phase I 
NCT01302405 
[99] Metastatic or unresectable solid tumors 
Phase I 
NCT01764477 
[100] 
Relapsed, locally advanced or metastatic pancreatic adenocarcinoma 
 
Phase I/II 
NCT01606579 
[101,102] 
Relapse or refractory Acute Myeloid Leukemia, advanced Chronic 
Myeloid Leukemia 
LRP5/6 BI 905677 
Phase 1 
NCT03604445 
[103] 
 
Metastatic or unresectable solid tumors 
8. Conclusion 
GC represents a heterogenous disease with very variable outcomes, independent of the tumor 
stage. Deregulation of the Wnt pathway is seen in approximately 50% of tumors [25] and therefore 
presents a novel therapeutic target. This review demonstrates that, through a higher understanding 
of the molecular intricacies of the Wnt pathway, several chemotherapeutic agents are currently in 
clinical trials, targeting the pathway intracellularly and at the receptor/ligand level. Nevertheless, 
these are primarily recruiting patients with advanced disease who have exhausted other treatment 
options. Future work will need to strengthen the prognostic evidence for Wnt dysregulation in 
predicting outcomes in patients with operable disease. This will then strengthen the argument for 
including Wnt-related adjuvant treatment options in patients at risk of developing recurrence and 
who have undergone potentially curative treatment, thus reducing recurrence and improving 
survival. In addition, Wnt signaling also regulates the many molecular processes involved in several 
stages of metastasis, which is the major cause of the mortality rate in GC patients. Thus, Wnt 
inhibitors could be effective anti-metastatic drugs for GC. However, considerable changes need to be 
made to the way anti-metastatic drugs are evaluated in preclinical trials, with a shift in the focus from 
funding bodies and trial design/patient recruitment to allow this area of therapy to fulfil its huge 
potential [104].  
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Abbreviations 
APC Adenomatous polyposis coli 
β-TrCP Beta-Transducin Repeat Containing E3 Ubiquitin Protein Ligase 
CAMKII calmodulin dependent protein kinase II 
CBP CREB-binding protein 
CDC Cell Division Cycle 42 
CDK Cyclin Dependent Kinase 
CK1α Casein kinase 1α 
CREB CAMP Responsive Element Binding Protein 
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DAAM Dishevelled Associated Activator Of Morphogenesis 
DAG 1,2-diacylglycerol 
DGO Diego 
DKK Dickkopf 
DVL Dishevelled 
FZD Frizzled 
FMI Flamingo 
GC gastric cancer 
GSK3α/β Glycogen synthase 3 
IP3 Inositol 1,4,5-triphosphate 
JUN Jun Proto-Oncogene, AP-1 Transcription Factor Subunit 
LGR Leucine-rich repeat-containing G-protein-coupled receptor 
LRP Low-density lipoprotein receptor-related protein 
NFκB Nuclear Factor Kappa B Subunit 1 
OC Oesophageal cancer 
PK LIM domain protein Prickle 
PLC Phospholipase C 
pTNM stage Pathological Tumor-Node-Metastasis stage 
RAC Rac Family Small GTPase 
RHO Rhodopsin 
ROCK Rho Associated Coiled-Coil Containing Protein Kinase 
ROR Receptor Tyrosine Kinase Like Orphan Receptor 
RNF Ring finger 
Ryk Receptor Like Tyrosine Kinase 
R SPO – Rspondin 
SFRP Secreted Frizzled-related protein 
SDC Syndican4 
TAZ Taffazin 
TCF/LEF T-cell factor/lymphoid enhancer factor 
TLE Groucho/ transducin-like Enhancer of Split  
VANG Van Gogh transmembrane protein 
YAP Yes associated protein 
VANG Van Gogh transmembrane protein 
YAP Yes associated protein 
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